Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of OBP-301 plus capecitabine chemoradiation in lower rectal and anal adenocarcinoma
jRCT2063260053Not yet recruiting
- Sponsor
- Oncolys BioPharma Inc.
- Start
- Aug 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of suratadenoturev in rectal adenocarcinoma, sponsored by Oncolys BioPharma Inc. Primary endpoints: Pathological complete response (pCR) rate and Adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
suratadenoturev
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2063260053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063260053.